The aim of the study was to compare denosumab and zoledronate efficacy in bone mass, bone
turnover markers (BTMs), Visual Analogue Scale (VAS) for leg and back, EuroQol Five-Dimension
(EQ-5D) scores, Quality of Life Questionnaire of the European Foundation for Osteoporosis-31
(QUALEFFO-31) scores, and Roland-Morris Disability Functioning Questionnaire (RMDQ) scores,
secondary fracture, complications and adverse events after lumbar fusion.